268 related articles for article (PubMed ID: 24224176)
1. How ocular surface disease impacts the glaucoma treatment outcome.
Kaštelan S; Tomić M; Metež Soldo K; Salopek-Rabatić J
Biomed Res Int; 2013; 2013():696328. PubMed ID: 24224176
[TBL] [Abstract][Full Text] [Related]
2. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives.
Ramli N; Supramaniam G; Samsudin A; Juana A; Zahari M; Choo MM
Optom Vis Sci; 2015 Sep; 92(9):e222-6. PubMed ID: 25730335
[TBL] [Abstract][Full Text] [Related]
3. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease.
Goldberg I; Graham SL; Crowston JG; d'Mellow G;
Clin Exp Ophthalmol; 2015 Apr; 43(3):214-20. PubMed ID: 25196488
[TBL] [Abstract][Full Text] [Related]
4. Preservatives in glaucoma medication.
Steven DW; Alaghband P; Lim KS
Br J Ophthalmol; 2018 Nov; 102(11):1497-1503. PubMed ID: 29973365
[TBL] [Abstract][Full Text] [Related]
5. Risk factors to develop ocular surface disease
in treated glaucoma or ocular hypertension patients.
Rossi GC; Pasinetti GM; Scudeller L; Raimondi M; Lanteri S; Bianchi PE
Eur J Ophthalmol; 2013; 23(3):296-302. PubMed ID: 23335308
[TBL] [Abstract][Full Text] [Related]
6. New strategies for the management of ocular surface disease in glaucoma patients.
Voicu L; Salim S
Curr Opin Ophthalmol; 2021 Mar; 32(2):134-140. PubMed ID: 33492867
[TBL] [Abstract][Full Text] [Related]
7. The prevalence of ocular surface complaints in Brazilian patients with glaucoma or ocular hypertension.
Costa VP; Marcon IM; Galvão Filho RP; Malta RF
Arq Bras Oftalmol; 2013; 76(4):221-5. PubMed ID: 24061832
[TBL] [Abstract][Full Text] [Related]
8. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice.
Holló G; Topouzis F; Fechtner RD
Expert Opin Pharmacother; 2014 Aug; 15(12):1737-47. PubMed ID: 24998246
[TBL] [Abstract][Full Text] [Related]
9. [Advances in preservative-free glaucoma drops].
Stefan C; Pop A; Cojocaru I
Oftalmologia; 2011; 55(2):3-6. PubMed ID: 21888063
[TBL] [Abstract][Full Text] [Related]
10. Glaucoma therapy and ocular surface disease: current literature and recommendations.
Anwar Z; Wellik SR; Galor A
Curr Opin Ophthalmol; 2013 Mar; 24(2):136-43. PubMed ID: 23542350
[TBL] [Abstract][Full Text] [Related]
11. Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis.
Harasymowycz P; Hutnik C; Rouland JF; Negrete FJM; Economou MA; Denis P; Baudouin C
Adv Ther; 2021 Jun; 38(6):3019-3031. PubMed ID: 33891269
[TBL] [Abstract][Full Text] [Related]
12. Understanding Ocular Surface Disease in Glaucoma: A Comparative Analysis of Symptoms and Objective Parameters.
Romano J; Ferreira N; Godinho G; Tomás R; Oliveira N; Sousa JP
Cureus; 2024 Feb; 16(2):e54070. PubMed ID: 38481920
[TBL] [Abstract][Full Text] [Related]
13. Influence of Treating Ocular Surface Disease on Intraocular Pressure in Glaucoma Patients Intolerant to Their Topical Treatments: A Report of 10 Cases.
Dubrulle P; Labbé A; Brasnu E; Liang H; Hamard P; Meziani L; Baudouin C
J Glaucoma; 2018 Dec; 27(12):1105-1111. PubMed ID: 30489502
[TBL] [Abstract][Full Text] [Related]
14. Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study.
Saade CE; Lari HB; Berezina TL; Fechtner RD; Khouri AS
Can J Ophthalmol; 2015 Apr; 50(2):132-6. PubMed ID: 25863853
[TBL] [Abstract][Full Text] [Related]
15. Ocular Surface Disease in Patients under Topical Treatment for Glaucoma.
Pérez-Bartolomé F; Martínez-de-la-Casa JM; Arriola-Villalobos P; Fernández-Pérez C; Polo V; García-Feijoó J
Eur J Ophthalmol; 2017 Nov; 27(6):694-704. PubMed ID: 28497458
[TBL] [Abstract][Full Text] [Related]
16. Conjunctival Goblet Cells, the Overlooked Cells in Glaucoma Treatment.
Tiedemann D; Mouhammad ZA; Utheim TP; Dartt DA; Heegaard S; Petrovski G; Kolko M
J Glaucoma; 2019 Apr; 28(4):325-333. PubMed ID: 30585937
[TBL] [Abstract][Full Text] [Related]
17. The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability.
Konstas AG; Labbé A; Katsanos A; Meier-Gibbons F; Irkec M; Boboridis KG; Holló G; García-Feijoo J; Dutton GN; Baudouin C
Expert Opin Drug Saf; 2021 Apr; 20(4):453-466. PubMed ID: 33478284
[No Abstract] [Full Text] [Related]
18. Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost.
Kumar S; Singh T; Ichhpujani P; Vohra S
Rom J Ophthalmol; 2019; 63(3):249-256. PubMed ID: 31687627
[No Abstract] [Full Text] [Related]
19. High Prevalence of Ocular Surface Disease Among Glaucoma Patients in Thailand.
Ruangvaravate N; Prabhasawat P; Vachirasakchai V; Tantimala R
J Ocul Pharmacol Ther; 2018 Jun; 34(5):387-394. PubMed ID: 29596033
[TBL] [Abstract][Full Text] [Related]
20. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells.
Ammar DA; Noecker RJ; Kahook MY
Adv Ther; 2010 Nov; 27(11):837-45. PubMed ID: 20931366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
